Skip to content
10-Q

Quarterly Report

Relay Therapeutics, Inc. RLAY

0001193125-26-206454

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 191.59M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$51.11M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$73.21M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $204.59M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $84.02M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $93.54M
Stockholders Equity Q1 2026 · Mar 31, 2026 $642.18M
Stockholders Equity Q1 2026 · Dec 31, 2025 $567.06M
Stockholders Equity Q1 2026 · Mar 31, 2025 $721.08M
Stockholders Equity Q1 2026 · Dec 31, 2024 $777.79M
Current Liabilities Q1 2026 · Mar 31, 2026 $29.75M
Current Liabilities Q1 2026 · Dec 31, 2025 $25.58M
Total Liabilities Q1 2026 · Mar 31, 2026 $57.43M
Total Liabilities Q1 2026 · Dec 31, 2025 $54.27M
Current Assets Q1 2026 · Mar 31, 2026 $658.46M
Current Assets Q1 2026 · Dec 31, 2025 $578.28M
Total Assets Q1 2026 · Mar 31, 2026 $699.61M
Total Assets Q1 2026 · Dec 31, 2025 $621.33M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.41
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.46
Eps Basic Q1 2026 · Mar 31, 2026 −$0.41
Eps Basic Q1 2026 · Mar 31, 2025 −$0.46
Sga Expense Q1 2026 · Mar 31, 2026 $11.03M
Sga Expense Q1 2026 · Mar 31, 2025 $18.74M
Net Income Q1 2026 · Mar 31, 2026 −$73.29M
Net Income Q1 2026 · Mar 31, 2025 −$77.07M
Operating Income Q1 2026 · Mar 31, 2026 −$78.59M
Operating Income Q1 2026 · Mar 31, 2025 −$84.87M
Revenue Q1 2026 · Mar 31, 2026 $3M
Revenue Q1 2026 · Mar 31, 2025 $7.68M
Capex Q1 2026 · Mar 31, 2025 $384K